{"id":"https://openalex.org/W2632016692","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.586","title":"Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).","display_name":"Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).","publication_year":2016,"publication_date":"2016-05-20","ids":{"openalex":"https://openalex.org/W2632016692","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.586","mag":"2632016692"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2016.34.15_suppl.586","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.586","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2016.34.15_suppl.586","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018738915","display_name":"Laura M. Spring","orcid":"https://orcid.org/0000-0001-8904-3514","observed_orcids":["https://orcid.org/0000-0001-8904-3514"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Laura Spring","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028403057","display_name":"Andrzej Niemierko","orcid":"https://orcid.org/0000-0002-8895-5500","observed_orcids":["https://orcid.org/0000-0002-8895-5500"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrzej Niemierko","raw_affiliation_strings":["Massachusetts General Hospital, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032332609","display_name":"Amy H. Comander","orcid":"https://orcid.org/0000-0002-1644-9297","observed_orcids":["https://orcid.org/0000-0002-1644-9297"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amy H. Comander","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035343389","display_name":"Kerry Lynn Reynolds","orcid":"https://orcid.org/0000-0002-7793-654X","observed_orcids":["https://orcid.org/0000-0002-7793-654X"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kerry Lynn Reynolds","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051966100","display_name":"Susan A. Sajer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan A. Sajer","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101601454","display_name":"Jennifer Adrienne Shin","orcid":"https://orcid.org/0000-0002-2323-9319","observed_orcids":["https://orcid.org/0000-0002-2323-9319"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer Shin","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063493321","display_name":"Elena F. Brachtel","orcid":"https://orcid.org/0000-0002-6109-2848","observed_orcids":["https://orcid.org/0000-0002-6109-2848"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elena F Brachtel","raw_affiliation_strings":["Massachusetts General Hospital, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027732826","display_name":"Michelle Connolly Specht","orcid":"https://orcid.org/0000-0002-0456-348X","observed_orcids":["https://orcid.org/0000-0002-0456-348X"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michelle Connolly Specht","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055568190","display_name":"Barbara Lynn Smith","orcid":"https://orcid.org/0000-0003-4281-665X","observed_orcids":["https://orcid.org/0000-0003-4281-665X"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Barbara L. Smith","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072565409","display_name":"Alphonse G. Taghian","orcid":"https://orcid.org/0000-0003-2211-9355","observed_orcids":["https://orcid.org/0000-0003-2211-9355","https://orcid.org/0000-0002-7306-2398"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alphonse G. Taghian","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010429902","display_name":"Jeffrey M. Peppercorn","orcid":"https://orcid.org/0000-0001-7138-6404","observed_orcids":["https://orcid.org/0000-0001-7138-6404"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey M. Peppercorn","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057580348","display_name":"Steven Jay Isakoff","orcid":"https://orcid.org/0000-0002-6677-1014","observed_orcids":["https://orcid.org/0000-0002-6677-1014"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven J. Isakoff","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017550097","display_name":"Beverly Moy","orcid":"https://orcid.org/0000-0003-3472-1140","observed_orcids":["https://orcid.org/0000-0003-3472-1140"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Beverly Moy","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5034972183","display_name":"Aditya Bardia","orcid":"https://orcid.org/0000-0003-4885-1157","observed_orcids":["https://orcid.org/0000-0003-4885-1157"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aditya Bardia","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210087915"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"34","issue":"15_suppl","first_page":"586","last_page":"586"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.7411999702453613,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.7411999702453613,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.24660000205039978,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.0032999999821186066,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.9269999861717224},{"id":"https://openalex.org/keywords/pertuzumab","display_name":"pertuzumab","score":0.8460000157356262},{"id":"https://openalex.org/keywords/neoadjuvant-chemotherapy","display_name":"neoadjuvant chemotherapy","score":0.8920000195503235},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.8040000200271606},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.7910000085830688},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":0.718999981880188},{"id":"https://openalex.org/keywords/pathological-complete-response","display_name":"pathological complete response","score":0.7839999794960022},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.8389999866485596},{"id":"https://openalex.org/keywords/left-ventricular-ejection-fraction","display_name":"left ventricular ejection fraction","score":0.8429999947547913},{"id":"https://openalex.org/keywords/localized-breast-cancer","display_name":"localized breast cancer","score":0.7020000219345093},{"id":"https://openalex.org/keywords/comparative-effectiveness","display_name":"comparative effectiveness","score":0.5059999823570251},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.5090000033378601},{"id":"https://openalex.org/keywords/mastectomy","display_name":"mastectomy","score":0.5149999856948853}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8683162927627563},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.8096926808357239},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.7443430423736572},{"id":"https://openalex.org/C2781164504","wikidata":"https://www.wikidata.org/wiki/Q1998021","display_name":"Pertuzumab","level":5,"score":0.7402235269546509},{"id":"https://openalex.org/C2780835546","wikidata":"https://www.wikidata.org/wiki/Q425122","display_name":"Epirubicin","level":4,"score":0.6618722677230835},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.606779932975769},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5285738110542297},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5111303925514221},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4796488881111145},{"id":"https://openalex.org/C2778292576","wikidata":"https://www.wikidata.org/wiki/Q6991934","display_name":"Neoadjuvant therapy","level":4,"score":0.47261857986450195},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.46922242641448975},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.4574223756790161},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4314080476760864},{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.43000054359436035},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3552458882331848},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.34883078932762146},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.26987549662590027},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.17753833532333374},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.10799974203109741}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2016.34.15_suppl.586","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.586","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2016.34.15_suppl.586","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8299999833106995}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2891322329","https://openalex.org/W2792780820","https://openalex.org/W4226340634","https://openalex.org/W4304013906","https://openalex.org/W2978397085","https://openalex.org/W2621635573","https://openalex.org/W4210869772","https://openalex.org/W7134230519","https://openalex.org/W2947076392","https://openalex.org/W3136458548"],"abstract_inverted_index":{"586":[0],"Background:":[1],"Based":[2],"on":[3],"improvement":[4],"in":[5,10,66,72,157,199,207,264,326],"pathologic":[6],"complete":[7],"response":[8],"(pCR)":[9],"the":[11,16,67,158,265],"NEOSPHERE":[12],"and":[13,24,47,55,59,99,102,138,179,185,220,261,283],"TRYPHAENA":[14],"studies,":[15],"FDA":[17],"approved":[18],"NA":[19,97,117,212],"pertuzumab":[20],"with":[21,36,51,87,104,114,150,168,177,190,225,247,251,269,328],"trastuzumab":[22],"(HP)":[23],"chemotherapy":[25],"for":[26,95,126,144,216,299],"HER2+":[27,127,153,301],"localized":[28,300],"BC.":[29,128],"These":[30],"studies":[31,285],"demonstrated":[32],"higher":[33,176,191],"pCR":[34,49,63,129,173,229,249,267,320,325],"rate":[35,174,230],"THP":[37,184,308],"(docetaxel+HP)":[38],"as":[39,132,181,254,290],"compared":[40,182,255],"to":[41,124,183,256,294],"TH":[42],"(pCR":[43,57],"45.8":[44],"vs.":[45],"29%),":[46],"high":[48,248],"rates":[50,250,268],"FEC":[52],"(5-fluorouracil,":[53],"epirubicin":[54],"cyclophosphamide)-THP":[56],"54.7%)":[58],"TCHP":[60,180,262,312],"(docetaxel,":[61],"carboplatin+HP,":[62],"63.6%).":[64],"However,":[65],"US,":[68],"doxorubicin/cyclophosphamide":[69],"(AC)":[70],"given":[71],"a":[73,116,171,197,226],"dose-dense":[74],"fashion":[75],"is":[76,82,279],"favored":[77],"over":[78],"FEC,":[79],"though":[80,236],"there":[81],"no":[83],"data":[84],"comparing":[85],"AC-THP":[86,178,232,252,260,304],"AC-TH":[88,121,222,316],"or":[89,120,196],"TCHP.":[90],"Here":[91],"we":[92],"report":[93],"outcomes":[94],"pertuzumab-containing":[96,118],"regimens":[98,278,298],"compare":[100],"effectiveness":[101,274],"toxicity":[103,192],"AC-TH.":[105],"Methods:":[106],"We":[107],"reviewed":[108],"patients":[109,149,165],"treated":[110],"at":[111],"our":[112],"institution":[113],"either":[115],"regimen":[119,200],"from":[122],"2011":[123],"2015":[125],"was":[130,175,188,223,245],"defined":[131],"ypT0/is":[133],"ypN0.":[134],"Fisher\u2019s":[135],"exact":[136],"test":[137],"logistic":[139],"regression":[140],"analysis":[141,159],"were":[142,155,209],"used":[143],"statistical":[145],"analysis.":[146],"Results:":[147],"Eighty":[148],"stage":[151],"II-III":[152],"BC":[154],"included":[156],"(stage":[160],"II":[161],"=":[162,234,241,306,310,314,318],"77.5%).":[163],"All":[164],"had":[166],"surgery,":[167],"62.5%":[169],"receiving":[170],"mastectomy.":[172],"AC-TH,":[186],"but":[187],"associated":[189,224,246],"requiring":[193],"dose":[194],"interruptions":[195],"change":[198],"(table":[201],"1).":[202],"No":[203],"statistically":[204,237],"significant":[205,239],"decreases":[206],"LVEF":[208],"seen":[210],"during":[211],"therapy.":[213],"After":[214],"controlling":[215],"ER":[217],"status,":[218],"age,":[219],"stage,":[221],"much":[227],"lower":[228],"than":[231],"(OR":[233],"0.39),":[235],"not":[238],"(p":[240],"0.15).":[242],"CEP17":[243],"duplication":[244,330],"(80%)":[253],"other":[257],"regimens.":[258],"Conclusions:":[259],"resulted":[263],"highest":[266],"similar":[270],"tolerability":[271],"overall.":[272],"Comparative":[273],"of":[275,286],"various":[276],"neoadjuvant":[277,297],"an":[280],"understudied":[281],"area":[282],"additional":[284],"predictive":[287],"biomarkers,":[288],"such":[289],"CEP17,":[291],"are":[292],"needed":[293],"help":[295],"personalize":[296],"breast":[302],"cancer.":[303],"(n":[305,309,313,317],"31)":[307],"17)":[311,319],"15)":[315],"64.5%":[321],"41.8%":[322],"60%":[323],"41.2%":[324],"tumors":[327],"CEP":[329],"80%":[331],"28.6%":[332],"66.7%":[333],"25%":[334],"%":[335],"planned":[336],"cycles":[337],"completed":[338],"71%":[339],"94.1%":[340],"73.3%":[341],"64.7%":[342]},"counts_by_year":[{"year":2020,"cited_by_count":1}],"updated_date":"2026-10-17T09:40:24.721904","created_date":"2017-06-30T00:00:00"}